KCA
Search
- Page Path
- HOME > Search
Original Article
- General
- Therapeutic Effect of Anti-inflammatory Tripeptide Cream in Hand-Foot Syndrome/Skin Reaction Related to Anticancer Drugs: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial
- Yaewon Yang, Jang-Hee Hahn, Min Seo Kim, Minkwan Jo, Yong-Pyo Lee, Hongsik Kim, Hee Kyung Kim, Jihyun Kwon, Ki Hyeong Lee, Hye Sook Han
- Cancer Res Treat. 2024;56(4):1050-1057. Published online June 5, 2024
- DOI: https://doi.org/10.4143/crt.2024.080
-
Abstract
PDF
Supplementary Material
PubReader
ePub - Purpose
Hand-foot syndrome (HFS) and hand-foot skin reaction (HFSR) are relatively common toxicities that interfere with the quality of life (QoL) of patients with cancer. Anti-inflammatory tripeptide cream (ATPC) is a complex formulation of anti-inflammatory tripeptides, the CD99-agonist Binterin and the Wnt-antagonist Winhibin. The present study aimed to assess the therapeutic effects of ATPC in HFS/HFSR associated with anticancer drugs.
Materials and Methods
This was a single-center, randomized, double-blind, placebo-controlled trial. Patients who developed grade 1 HFS/HFSR after systemic anticancer treatments were enrolled, and randomly assigned to receive either ATPC or placebo cream (PC) and followed up at 3-week intervals for up to 9 weeks. Primary endpoint was the development of grade ≥ 2 HFS/HFSR.
Results
Between April 2019 and July 2022, 60 patients (31 in the ATPC and 29 in the PC group) completed the study. The incidence of grade ≥ 2 HFS/HFSR was significantly lower in the ATPC than in the PC group (25.8% vs. 51.7%, p=0.039). The ATPC showed trends towards a better QoL score, assessed by a HFSR and QoL questionnaire at 9 weeks (26.0 vs. 29.9, p=0.574), and a lower frequency of discontinuation, interruption, or dose reduction of anticancer drugs (51.6% vs. 58.6%, p=0.586) than the PC group over 9 weeks, though without statistical significance.
Conclusion
Our results showed that ATPC significantly decreased the development of grade ≥ 2 HFS/HFSR in patients already with HFS/HFSR. Therefore, ATPC may be an effective treatment for HFS/HFSR associated with anticancer drugs. -
Citations
Citations to this article as recorded by
- The Effect of Topical Heparin Gel on Reducing Hand–Foot Syndrome Symptoms in Cancer Patients Treated with Capecitabine
Maede Mirjalili, Yaser Salehinajafabadi, Hadi Raeisi Shahraki, Rohollah Masumi
South Asian Journal of Cancer.2025;[Epub] CrossRef - Advanced statistical methods for the analysis of data in cosmetic science studies
Maheshvari Patel, Nayan Patel, Sanyukta Dhara, Shambhavi Srivastava
International Journal of Clinical Trials.2025;[Epub] CrossRef - Chemotherapy-induced hand-foot syndrome among Chinese inpatients: a qualitative descriptive study in Shanghai
Jie Zhang, Lei Huang, Qianyun He, Xueqin Deng, WenQi Xi, Mei Wang
BMJ Open.2025; 15(11): e102919. CrossRef
- The Effect of Topical Heparin Gel on Reducing Hand–Foot Syndrome Symptoms in Cancer Patients Treated with Capecitabine
- 4,406 View
- 222 Download
- 3 Web of Science
- 3 Crossref
First
Prev
